Banc de Sang i Teixits
22
3
3
16
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 60/100
13.6%
3 terminated/withdrawn out of 22 trials
84.2%
-2.3% vs industry average
5%
1 trials in Phase 3/4
0%
0 of 16 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (22)
Red Blood Cells From Umbilical Cord for Transfusion of Preterm Infants
Role: collaborator
A Study of Allogenic Natural Killer Cells in Combination With Trastuzumab and Pertuzumab in Adult Patients With Refractory Metastatic Her2 Positive Breast Cancer. NK-ACT-BC_2020
Role: collaborator
Evaluation of a Pragmatic Approach to Adoptive Cell Therapy (ACT) Using an IL2 Analog (ANV419) vs High Dose IL2 After Tumor Infiltrating Lymphocytes (TIL) Therapy in Patients With Melanoma, NSCLC and Cervical Cancer (PragmaTIL)
Role: collaborator
Assessment of the Safety and Tolerability of ex Vivo Next-generation Neoantigen-selected Tumor-infiltrating Lymphocyte (TIL) Therapy in Advanced Epithelial Tumors and Immune Checkpoint Blockade (ICB) Resistant Solid Tumors
Role: collaborator
Transfusion of Red Blood Cells, Tranexamic Acid and Fibrinogen Concentrate for Severe Trauma Hemorrhage at Pre-hospital Phase of Care.
Role: lead
Virus-specific Activated T Lymphocytes From a Donor in Hematopoietic Progenitor Transplanted Patients
Role: lead
Cell Therapy for Chronic Traumatic Cervical Incomplete Spinal Cord Injury
Role: lead
Plasma Exchange Therapy for Post- COVID-19 Condition: A Pilot, Randomized Double-Blind Study
Role: collaborator
Study Protocol to Evaluate Clinical and Imaging Results of Knee Fresh Osteochondral Allografts
Role: collaborator
Efficacy and Safety Evaluation of Mesenchymal Stem Cells for the Treatment of Patients With Respiratory Distress Due to COVID-19
Role: lead
Prophylactic Infusion of Donor Lymphocytes in Cord Blood Transplantation
Role: lead
Plasma for Early Treatment in Non-hospitalised Mild or Moderate COVID-19 Patients
Role: collaborator
Mesenchymal Stromal Cells for the Treatment of Non-union Fractures of Long Bones
Role: lead
A Clinical Trial to Asses Efficacy and Safety of Cord Blood Eye Drops in Neurotrophic Keratopathy
Role: lead
Intrathecal Administration of Expanded Wharton's Jelly Mesenchymal Stem Cells in Chronic Traumatic Spinal Cord Injury
Role: lead
Autologous Mesenchymal Stromal Cells for Multiple Sclerosis
Role: lead
Mesenchymal Stem Cells in Osteonecrosis of the Femoral Head
Role: lead
Safety Study of Mesenchymal Stem Cells and Spinal Fusion
Role: lead
Mesenchymal Stromal Cells for Degenerative Meniscus Injury
Role: lead
Allogeneic Mesenchymal Stromal Cells in Elderly Patients With Hip Fracture
Role: lead